+44 (0)20 3910 4640 hello@symmetron.net

Alex Diamantopoulos, MSc

Alex is the Director and founder of Symmetron.

He has expertise in many areas of health economic evaluation. He has developed studies and provided strategic advice to help many companies overcoming the challenges in generating, synthesising and evaluating health economic evidence in order to achieve market access. He has designed economic evaluations and other market access tools in Europe, USA, Canada, Australia and several countries of East Asia.

His research interests include decision-analytic modelling, use of statistical methods in economic evaluations and indirect treatment comparisons. He has completed research in a range of therapeutic areas including oncology, diabetes, rheumatoid arthritis, heart disease, mental health and behavioural conditions, neurological conditions, paediatric diseases, diagnostics, and various applications of medical devices. An economist by training, Alex has an MSc from the University of Birmingham.

Publications 

Rinciog C, Sawyer L, Diamantopoulos A, et al. Costeffectiveness of an insertable cardiac monitor in a high-risk population in the UK. Open Heart 2019;6:e001037

Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review. PharmacoEconomics. 2018;36(7):779-807

Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics. 2017 Apr;35(4):479-491.

Diamantopoulos A, Schoof N, Esser D, LeReun C. Resource Use In Idiopathic Pulmonary Fibrosis: Influence of Disease Progression and Exacerbations. Poster presented at the European ISPOR meeting 2016: PRS69

Rinciog C, Watkins M, Chang S, Maher T, LeReun C, Esser D, Diamantopoulos A. Nintedanib cost-effectiveness in idiopathic pulmonary fibrosis in the UK. PharmacoEconomics, published online: 31 December 2016

Diamantopoulos A, Sawyer LM,Lip GY, Witte KK, Reynolds MR, Fauchier L, Thijs V, Brown B, Quiroz Angulo ME, Diener HC. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. Int J Stroke. 2016 Apr 11 (3):302-12

Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. Pharmacoeconomics 2014 Aug 32(8):775-87.

Hallinen T, Soini EJ, Diamantopoulos A, Dejonckheere F, Vihervaara V, Hautala A, Aalto K. Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland. Ann Rheum Dis  2013;71:258-259

Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thromb Haemost. 2013 Oct 31;110(5):987-94.

Diamantopoulos A, Sawyer L, Ogale S, Dejonckheere F. Validity of cost and utility results? Pharmacoeconomics. 2012 Oct 1;30(10):977; author reply 977-8.

McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. J Med Econ. 2012;15(5):817-28.

Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, Ricciardi W. Economic evaluation of tocilizumab combination in the treatment of moderate to severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576-85. Epub 2012 Mar 9.

Duran A, Sengupta N, Diamantopoulos A, et al. Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective. Pharmacoeconomics. 2012 Feb 1;30(2):87-101.

Duran A, Sengupta N, Diamantopoulos A, et al. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective. J Med Econ. 2011;14(6):824-34.

Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Björholt I. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):601-15.

Lereun C, Wells P, Diamantopoulos A, Rasul F, Lees M, Sengupta N. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. J Med Econ. 2011; 14(2): 238-44. Epub 2011 Mar 9.

Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-Effectiveness of Rivaroxaban versus Enoxaparin for the Prevention of Postsurgical Venous Thromboembolism in Canada. Thromb Haemost. 2010 Oct;104(4):760-70.

Kielhorn A, Porter D, Diamantopoulos A, Lewis G. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin. 2008; 24(9): 2639-50.

Brown B, Diamantopoulos A, Bernier J, Schöflski P, Hieke K, Mantovani L, Launois R, Griebsch I, Robinson P. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland and the United Kingdom. Value in health. 2008; 11(5): 791-799.

Tilden DP, Mariz S, O’Bryan-Tear G, Bottomley J, Diamantopoulos A. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2007; 25(1): 39-54

Podium presentations

Diamantopoulos A, LeReun C, Rasul F, Lees M, Kubin M. Indirect comparisons of rivaroxaban vs alternative prophylaxes for the prevention of venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) or total knee replacement (TKR). Fifth Annual Meeting of Health Technology Assessment International. Montreal, Canada. July 2008

Pompen M, Diamantopoulos A, Kievit W, Moers R, Kielhorn A. Economic consequences of providing rituximab as a treatment alternative for rheumatoid arthritis in the Netherlands. ISPOR 10th Annual European Congress. Dublin, Ireland. October 2007